Nanologica AB (publ) (STO:NICA)

Revenue by Segment

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Chromatography	21.13M	14.54M	-	1.56M	1.91M
Drug Development - DD	-	-	-	-	10.36M
Unallocated Business Support	-	-	-	-	642.00K
Total	21.13M	14.54M	-	1.56M	12.91M

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Sweden	-	-	-	-	9.24M
China	18.28M	8.43M	654.00K	699.00K	1.31M
India	182.00K	5.92M	188.00K	128.00K	-
United States of America (USA)	77.00K	-	-	276.00K	103.00K
Rest of The World	1.06M	175.00K	601.00K	452.00K	1.92M
Turkey	1.52M	21.00K	-	-	343.00K
Total	21.13M	14.54M	1.44M	1.56M	12.91M

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 2, 2026

Data Sources Report a data error